These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 18316282)

  • 21. Food and Drug Administration approval of buprenorphine-naloxone for office treatment of addiction.
    Resnick RB
    Ann Intern Med; 2003 Feb; 138(4):360. PubMed ID: 12585846
    [No Abstract]   [Full Text] [Related]  

  • 22. Opiate addiction and prescription drug abuse: a pragmatic approach.
    Hasan KM; Hasan OK
    W V Med J; 2010; 106(4 Spec No):84-5. PubMed ID: 21932759
    [No Abstract]   [Full Text] [Related]  

  • 23. Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians.
    Johanson CE; Arfken CL; di Menza S; Schuster CR
    Drug Alcohol Depend; 2012 Jan; 120(1-3):190-5. PubMed ID: 21862241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?
    Mendelson J; Jones RT
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S29-37. PubMed ID: 12738348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using buprenorphine for outpatient opioid detoxification.
    Manlandro JJ
    J Am Osteopath Assoc; 2007 Sep; 107(9 Suppl 5):ES11-6. PubMed ID: 17908825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accessing opiate dependence treatment medications: buprenorphine products in an office-based setting.
    Leshner AI
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S103-4. PubMed ID: 12738354
    [No Abstract]   [Full Text] [Related]  

  • 27. Opiate dependence treatment with buprenorphine: one year's experience in a family practice residency setting.
    Colameco S; Armando J; Trotz C
    J Addict Dis; 2005; 24(2):25-32. PubMed ID: 15784521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opioid dependence: rationale for and efficacy of existing and new treatments.
    Fiellin DA; Friedland GH; Gourevitch MN
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S173-7. PubMed ID: 17109303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reimbursement and practice policies among providers of buprenorphine-naloxone treatment.
    Wisniewski AM; Dlugosz MR; Blondell RD
    Subst Abus; 2013; 34(2):105-7. PubMed ID: 23577902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine.
    Harris DS; Jones RT; Welm S; Upton RA; Lin E; Mendelson J
    Drug Alcohol Depend; 2000 Dec; 61(1):85-94. PubMed ID: 11064186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early experience with Suboxone maintenance therapy in Hungary.
    Demetrovics Z; Farkas J; Csorba J; Németh A; Mervó B; Szemelyácz J; Fleischmann E; Kassai-Farkas A; Petke Z; Oroján T; Rózsa S; Rigó P; Funk S; Kapitány M; Kollár A; Rácz J
    Neuropsychopharmacol Hung; 2009 Dec; 11(4):249-57. PubMed ID: 20150662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine.
    Compton P; Ling W; Moody D; Chiang N
    Drug Alcohol Depend; 2006 Mar; 82(1):25-31. PubMed ID: 16144748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anesthesia for patients on buprenorphine.
    Bryson EO; Lipson S; Gevirtz C
    Anesthesiol Clin; 2010 Dec; 28(4):611-7. PubMed ID: 21074741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Consensus statement on office-based treatment of opioid dependence using buprenorphine.
    Fiellin DA; Kleber H; Trumble-Hejduk JG; McLellan AT; Kosten TR
    J Subst Abuse Treat; 2004 Sep; 27(2):153-9. PubMed ID: 15450648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence.
    Bridge TP; Fudala PJ; Herbert S; Leiderman DB
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S79-85. PubMed ID: 12738352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.
    Alho H; Sinclair D; Vuori E; Holopainen A
    Drug Alcohol Depend; 2007 Apr; 88(1):75-8. PubMed ID: 17055191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?
    Blum K; Chen TJ; Bailey J; Bowirrat A; Femino J; Chen AL; Simpatico T; Morse S; Giordano J; Damle U; Kerner M; Braverman ER; Fornari F; Downs BW; Rector C; Barh D; Oscar-Berman M
    Mol Neurobiol; 2011 Dec; 44(3):250-68. PubMed ID: 21948099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Buprenorphine Formulations: Clinical Best Practice Strategies Recommendations for Perioperative Management of Patients Undergoing Surgical or Interventional Pain Procedures.
    Jonan AB; Kaye AD; Urman RD
    Pain Physician; 2018 Jan; 21(1):E1-E12. PubMed ID: 29357325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in the treatment of opiate addiction.
    Fudala PJ; Woody GW
    Curr Psychiatry Rep; 2004 Oct; 6(5):339-46. PubMed ID: 15355756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Should high-dose buprenorphine be withdrawn from the French market?].
    Rolland B; Muyssen A; Danel T; Cottencin O
    Rev Epidemiol Sante Publique; 2013 Apr; 61(2):91-2. PubMed ID: 23489947
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.